NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit

NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit

NewAmsterdam Pharma (NASDAQ:NAMS) Chief Financial Officer Ian Somaiya said the company remains encouraged by early observations from its PREVAIL cardiovascular outcomes trial and reiterated plans to provide a mid-year update on study timelines during remarks at Guggenheim’s 2026 Emerging Outlook Bio

Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit

Executives from Alumis (NASDAQ:ALMS) outlined recent clinical results, upcoming regulatory milestones, and pipeline priorities during a discussion at the Guggenheim Emerging Outlook Biotech Summit 2026. Phase III psoriasis data highlights for envudeucitinib President and CEO Martin Babler said Alumis is a “precision immunology company” focused on TYK2 as a genomically validated target. The company has multiple TYK2 inhibitors in clinical develop…

Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit

Celldex Therapeutics (NASDAQ:CLDX) executives used a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline upcoming clinical milestones for barzolvolimab across multiple allergic and inflammatory indications, provide an update on long-term chronic spontaneous urticaria (CSU) data that has been discussed with physicians, and review early progress for its bispecific program CDX-622. Pipeline execution […]